Tag: PD-L1 Inhibitor Therapy

Home / PD-L1 Inhibitor Therapy

Categories

Atezolizumab and hyaluronidase-tqjs is approved by FDA for subcutaneous injection

On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications co...
pd-l1-inhibitor-therapy

Scan the code